gemcitabine

Open Access
Anti-tumor Effects of Erlotinib via Thymidylate Synthase Down-regulation in Pancreatic Cancer Cells
SATOSHI TABUCHI, TETSURO TOMINAGA, TOMOSHI TSUCHIYA, RYOICHIRO DOI, JYUNICHI ARAI, TAKASHI NONAKA, TAKURO MIYAZAKI, TATSUO INAMINE, KAZUHIRO TSUKAMOTO and KEITARO MATSUMOTO

Anticancer Research February 2025, 45 (2) 503-510; DOI: https://doi.org/10.21873/anticanres.17439
You have access
Targeting EGFR Activation to Overcome Gemcitabine Resistance in Cholangiocarcinoma
SONEXAI KIDOIKHAMMOUAN, WORACHART LERT-ITTHIPORN, RAKSAWAN DEENONPOE, CHARUPONG SAENGBOONMEE, SUMALEE OBCHOEI, SOPIT WONGKHAM and WUNCHANA SEUBWAI

Anticancer Research December 2024, 44 (12) 5393-5404; DOI: https://doi.org/10.21873/anticanres.17366
Open Access
First-line Chemotherapy in Combination With Oral Recombinant Methioninase and a Low-methionine Diet for a Stage IV Inoperable Pancreatic-Cancer Patient Resulted in 40% Tumor Reduction and an 86% CA19-9 Biomarker Decrease
MOTOKAZU SATO, QINGHONG HAN, CHIHIRO HOZUMI, HIDEO KUJIRAOKA, KOHEI MIZUTA, SEI MORINAGA, BYUNG MO KANG, NORITOSHI KOBAYASHI, YASUSHI ICHIKAWA, ATSUSHI NAKAJIMA and ROBERT M. HOFFMAN

Anticancer Research September 2024, 44 (9) 3885-3889; DOI: https://doi.org/10.21873/anticanres.17215
You have access
Enhanced Anti-tumor Effect of Flavopiridol in Combination With Gemcitabine in Pancreatic Cancer
KWANG HYUN CHUNG, IN RAE CHO, WOO HYUN PAIK, YONG-TAE KIM, SANG HYUB LEE and JI KON RYU

Anticancer Research March 2024, 44 (3) 1097-1108; DOI: https://doi.org/10.21873/anticanres.16905
You have access
Safety and Efficacy of Gemcitabine Plus Cisplatin Against Recurrent/Metastatic Nasopharyngeal Carcinoma: A Retrospective Study
HIROYUKI KODAMA, SHIGENORI KADOWAKI, TAIKO NAKAZAWA, YUKI MATSUBARA, YUKIYA NARITA, KAZUNORI HONDA, TOSHIKI MASUISHI, HIROYA TANIGUCHI, MASASHI ANDO, YUTARO KOIDE, HIROYUKI TACHIBANA, TAKESHI KODAIRA, MICHI SAWABE, HOSHINO TERADA, SHINTARO BEPPU, DAISUKE NISHIKAWA, HIDENORI SUZUKI, NOBUHIRO HANAI and KEI MURO

Anticancer Research March 2024, 44 (3) 1227-1232; DOI: https://doi.org/10.21873/anticanres.16918
You have access
A Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer Refractory to Gemcitabine Monotherapy
MARIKO NISHIOKA, NAOHIRO OKANO, MASASHI WAKABAYASHI, TAKASHI IKENO, MASATO HAYASHI, TOMONORI MIZUTANI, FUMIO NAGASHIMA and JUNJI FURUSE

Anticancer Research March 2024, 44 (3) 1233-1239; DOI: https://doi.org/10.21873/anticanres.16919
You have access
8-Chloroadenosine Induces ER Stress and Apoptotic Cell Death in Cholangiocarcinoma Cells
JOMNARONG LERTSUWAN, JISNUSON SVASTI and JUTAMAAD SATAYAVIVAD

Anticancer Research December 2023, 43 (12) 5425-5436; DOI: https://doi.org/10.21873/anticanres.16746
You have access
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel
YASUSHI IDE, TAIGA OTSUKA, MOTOTSUGU SHIMOKAWA, FUTA KOGA, YUJIRO UEDA, JUNICHI NAKAZAWA, AZUSA KOMORI, SATOSHI OTSU, SHIHO ARIMA, MASARU FUKAHORI, AKITAKA MAKIYAMA, YUDAI SHINOHARA, SHOHEI UENO, HIROKI TAGUCHI, TAKUYA HONDA, TARO SHIBUKI, KENTA NIO, NORIO URESHINO, TOSHIHIKO MIZUTA, KENJI MITSUGI and TSUYOSHI SHIRAKAWA

Anticancer Research April 2023, 43 (4) 1817-1826; DOI: https://doi.org/10.21873/anticanres.16335
Open Access
Recombinant Thrombomodulin Has Anti-tumor Effects and Enhances the Effects of Gemcitabine for Pancreatic Cancer Through G-protein Coupled Receptor 15
KENEI FURUKAWA, JIANHUA LING, YICHEN SUN, YU LU, JIE FU, RUI MARUKUCHI and PAUL J. CHIAO

Anticancer Research October 2022, 42 (10) 4679-4687; DOI: https://doi.org/10.21873/anticanres.15972
Open Access
The Effects of Treatment on Peripheral Blood Immune Cell Profile in Pancreatic Ductal Adenocarcinoma (PDAC)
SKAISTE TULYTE, DAINIUS CHARACIEJUS, REDA MATUZEVICIENE, AUSRA JANIULIONIENE, MANTAS RADZEVICIUS, TADAS ZVIRBLIS and AUDRIUS SILEIKIS

Anticancer Research June 2022, 42 (6) 3067-3073; DOI: https://doi.org/10.21873/anticanres.15794

Main menu

User menu

Search

gemcitabine

Pages